Abstract:Immune checkpoint inhibitors (ICI) have recently emerged as a treatment option for selected patients with advanced non-small-cell lung cancer (NSCLC). However, there is a lack of effective biomarker to predict the treatment response and monitor disease progression. In this prospective observational study, we aimed to investigate the predictive and prognostic value of folate receptor-positive circulating tumor cell (FR+CTC), a well-established lung cancer biomarker, in advanced NSCLC patients treated with ICIs. Advanced NSCLC patients with at least one measurable lesion and expected to undergo ICIs treatment were recruited. Peripheral blood samples were collected from each participant at baseline, after each cycle of ICI treatment, and on disease progression. FR+CTCs were enumerated by using negative enrichment and ligand-targeted polymerase chain reaction methods. Treatment efficacy was analyzed according to the iRECIST criteria. The correlation of FR+CTC level and its dynamic changes with radiological responses was evaluated. Of the 35 patients, 17 received first-line treatment, 10 received second-line treatment, and 8 received third-line treatment or above. CTCs were detected (≥8.7FU/3ml) in 80.0% of patients at baseline. The baseline CTC of first-line/second-line therapy patients was significantly higher than that of third-line and above therapy patients (median values 16.68 vs 8.36, P=0.017). Meanwhile, there was no significant difference in baseline CTC values between different pathological subtypes and whether PD-L1 was expressed or not. For the radiological responses, after at least two cycles of ICI treatment, PR, SD, and PD were found in 10, 8, and 4 patients, respectively. The CTC count in the PD group at baseline was significant higher than that of the disease control (PR+SD) group (P=0.033). Similarly, the CTC value after two cycles of ICI treatment in PD group (17.84 ± 7.03) was higher than SD/PR group (12.50 ± 4.94), but not statistically significant (P=0.081). However, the changes of CTCs after one or two cycles of immunotherapy were poorly related to the treatment response (P>0.05), perhaps because of the polarization trend of CTC changes in the PR group after treatment. In sum, these data confirm the predictive significance of CTCs in advanced NSCLC patients treated with immune checkpoint inhibitors. The baseline CTCs value correlated significantly with radiological response. Further studies are needed to confirm whether CTCs can be used as a prognostic factor for advanced non-small cell lung cancer.

156P: Correlation of Baseline Value of Folate Receptor-Positive Circulating Tumor Cells and Efficacy of Pemetrexed and Dynamic Monitoring Study in NSCLC Patients Receiving First-Line Platinum-Based Chemotherapy

Abstract 2252: Correlation of Baseline Value of Folate Receptor-Positive Circulating Tumor Cells and Efficacy of Pemetrexed and Dynamic Monitoring Study in Non-Small Cell Lung Cancer Patients Receiving First-Line Platinum-Based Chemotherapy

Folate Receptor-Positive Circulating Tumor Cells As a Predictive Biomarker for the Efficacy of First-Line Pemetrexed-Based Chemotherapy in Patients with Non-Squamous Non-Small Cell Lung Cancer

Efficacy of Pemetrexed Plus Platinum Doublet Chemotherapy As First-Line Treatment for Advanced Nonsquamous Non-Small-cell-lung Cancer: a Systematic Review and Meta-Analysis.

P1.07-031 Clinical Evaluation of Folate Receptor-Positive Circulating Tumor Cells Detection in Patients with Small Cell Lung Cancer: Topic: Molecular Changes

Predictive and Prognostic Value of Folate Receptor-Positive Circulating Tumor Cells in Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy

P2.03b-092 Predictive and Prognostic Effect of Circulating Tumor Cells in Non-Small Cell Lung Cancer Treated with Targeted Therapy: Topic: Biomarkers

MA15.09 Dynamic Monitoring and Predictive Value of Circulating Tumor Cells in EGFR Mutant Advanced NSCLC Patients Treated with First-Line EGFR-TKIs

Mutational Landscape of Cfdna Identifies Distinct Molecular Features Associated with Therapeutic Response to First-Line Platinum-Based Doublet Chemotherapy in Patients with Advanced NSCLC.

Circulating Tumor Cells and Evaluation of Targeted Therapy Effect in Egfr Mutation/Alk Translocation Metastatic Non-Small Cell Lung Cancer

1332P Prognostic Value of Baseline and Dynamic Change Value of CTC in Advanced NSCLC Patients Treated with Immune Checkpoint Inhibitor-Based Therapy

P2.04-57 Predictive and Prognostic Value of CTC Monitoring in Advanced NSCLC Patients Treated with Immune Checkpoint Inhibitors

Molecular Analysis of Cell-Free DNA to Identify Distinct Molecular Mutational Burden and Its Effect on First-Line Chemotherapy in Patients with NSCLC from a Phase III Trial.

Dynamic Monitoring and Predictive Value of Circulating Tumor Cells in EGFR-Mutated Advanced Non-Small-Cell Lung Cancer Patients Treated With First-Line EGFR Tyrosine Kinase Inhibitors

The Efficacy of Pemetrexed Combined Cis-platinum Chemotherapy for Patients with Advanced Non Small Cell Lung Cancer and the Effect on Serum Tumor Markers

Correlation Between Thymidylate Synthase Gene Polymorphisms and Efficacy of Pemetrexed in Advanced Non-Small Cell Lung Cancer

Predictive Value of Unmethylated RASSF1A on Disease Progression in Non-Small Cell Lung Cancer Patients Receiving Pemetrexed-Based Chemotherapy

[A Randomized, Controlled, Multicenter Clinical Trial Comparing Pemetrexed/cisplatin and Gemcitabine/cisplatin As First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer].

Prognostic Prediction of Pemetrexed-Platinum Chemotherapeutic Regimen for NSCLC by Serum Metabolomics.

Clinical Observation and Prognostic Analysis of Pemetrexed Plus Platinum As First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer.

Blood T cell diversity associated with the prognosis of advanced non-small cell lung carcinoma treated with first-line pemetrexed based chemotherapy